Pittsburgh Seeks Breast Cancer Patients for Study on Coping

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

PITTSBURGH--The University of Pittsburgh Cancer Institute’s Division of Behavioral Medicine and Oncology is seeking young women with breast cancer for a research study on helping families cope with cancer.

PITTSBURGH--The University of Pittsburgh Cancer Institute’s Division of Behavioral Medicine and Oncology is seeking young women with breast cancer for a research study on helping families cope with cancer.

The women will participate in educational and support groups for couples to discuss coping with a chronic illness, stress management skills, family communication, and parenting concerns. These groups, led by an oncology nurse and a health psychologist, will meet 1½ hours once a week for 8 weeks.

In addition, groups for children ages 3 to 12 may be available and would take place at the same time as the parent groups. The children will receive support and develop their skills for coping with feelings and managing stress.

To be eligible for this study, women must be premenopausal and have been diagnosed with breast cancer in the past 5 years, have a partner, and have children between the ages of 3 and 12. For more information, call 412-624-4806.

Recent Videos
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content